Treatment options for localized prostate cancer

American Family Physician

Volumn 84, Issue 4, 2011, Pages 413-420

  Mohan, Ravinder ^a   Schellhammer, Paul F ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL EFFECTIVENESS; COMORBIDITY; CRYOTHERAPY; ENTEROPATHY; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LAPAROSCOPIC SURGERY; LIFE EXPECTANCY; PATIENT SAFETY; PRACTICE GUIDELINE; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; ROBOTICS; SURVIVAL TIME; TREATMENT INDICATION; URINE INCONTINENCE;

EID: 80051750469     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. American Cancer Society. What are the key statistics about prostate cancer? http://www.cancer.org/Cancer/ProstateCancer/DetailedGuide/prostate-cancer-key-statistics. Accessed June 4, 2010.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
3. National Cancer Institute. Cancer advances in focus: prostate cancer. http://www.cancer.gov/cancertopics/factsheet/cancer-advances-in-focus/FS12_7.pdf. Accessed July 9, 2011.
4. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007;178(3 pt 2):S14-S19.
5. Parker C, Muston D, Melia J, Moss S, Dearnaley D. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer. 2006;94(10):1361-1368.
6. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293(17):2095-2101.
7. Bill-Axelson A, Holmberg L, Ruutu M, et al.; Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352(19):1977-1984.
8. Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst. 2010;102(13):950-958.
9. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol. 2005;23(32):8165-8169.
10. Harlan SR, Cooperberg MR, Elkin EP, et al. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol. 2003;170(5):1804-1807.
11. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst. 2006;98(16):1134-1141.
12. Shavers VL, Brown ML, Potosky AL, et al. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med. 2004;19(2):146-155.
13. Fowler FJ Jr, McNaughton Collins M, Albertsen PC, Zietman A, Elliott DB, Barry MJ. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA. 2000;283(24):3217-3222.
14. Cohen H, Britten N. Who decides about prostate cancer treatment? A qualitative study. Fam Pract. 2003;20(6):724-729.
15. Mohan R, Beydoun H, Barnes-Ely ML, et al. Patients' survival expectations before localized prostate cancer treatment by treatment status. J Am Board Fam Med. 2009;22(3):247-256.
16. Beydoun HA, Mohan R, Beydoun MA, Davis J, Lance R, Schellhammer P. Development of a scale to assess patient misperceptions about treatment choices for localized prostate cancer. BJU Int. 2010;106(3):334-341.
17. National Comprehensive Cancer Network. Prostate cancer. 2010 Practice guidelines in oncology v.2. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (registration required). Accessed June 4, 2010.
18. Wolf AM, Wender RC, Etzioni RB, et al.; American Cancer Society Prostate Cancer Advisory Committee. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60(2):70-98.
19. Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst. 2006;98(21):1521-1527.
20. Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol. 2006;175(5):1605-1612.
21. National Comprehensive Cancer Network. Prostate cancer.2010 Practice guidelines in oncology v.2. Prostate cancerearly detection. http://www.nccn.org/professionals/physician_gls/PDF/prostate_detection.pdf (registration required). Accessed October 14, 2010.
22. Post PN, Hansen BE, Kil PJ, Janssen-Heijnen ML, Coebergh JW. The independent prognostic value of comorbidity among men aged < 75 years with localized prostate cancer: a population-based study. BJU Int. 2001;87(9):821-826.
23. Hoffman RM, Stone SN, Espey D, Potosky AL. Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA. BMC Cancer. 2005;5:27.
24. Mohan R, Beydoun H, Davis J, Lance R, Schellhammer P. Feasibility of using guidelines to choose treatment for prostate cancer. Can J Urol. 2010;17(1):4975-4984.
25. Agency for Healthcare Research and Quality. Comparative effectiveness of therapies for clinically localized prostate cancer. Executive summary. http://www.effectivehealthcare.ahrq.gov/ehc/products/9/79/2008_0204ProstateCancerExecSum.pdf. Accessed June 4, 2010.
26. Agency for Healthcare Research and Quality. Treating prostate cancer. A guide for men with localized prostate cancer. http://www.effectivehealthcare.ahrq.gov/ehc/products/9/98/ProstateCancerConsumer.pdf. Accessed June 4, 2010.
27. van den Bergh RC, Roemeling S, Roobol MJ, et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol. 2009;55(1):1-8.
28. van den Bergh RC, Essink-Bot ML, Roobol MJ, et al. Anxiety and distress during active surveillance for early prostate cancer. Cancer. 2009;115(17):3868-3878.